reltecimod   Click here for help

GtoPdb Ligand ID: 13721

Synonyms: AB 103 | AB103 | p2TA
Compound class: Peptide
Comment: Reltecimod is a mimetic peptide that prevents binding of bacterial superantigens to the host target of CD28 [1]. It entered clinical development as an immunomodulating agent, with the aim of reducing the acute inflammatory response observed in patients with necrotizing soft tissue infections (NSTIs) that can lead to organ failure [2-3].
2D Structure
Click here for help

2D Structure

An image of the ligand's 2D structure. For small molecules with SMILES these are drawn using the NCI/CADD Chemical Identifier Resolver. Click on the image to access the chemical structure search tool with the ligand pre-loaded in the structure editor. For other types of ligands, e.g. longer nucleotides and peptides, a manually drawn representation of the molecule may be provided.

✖
Click here for structure editor
SMILES / InChI / InChIKey
Click here for help

SMILES / InChI / InChIKey

SMILES (Simplified Molecular Input Line Entry Specification) A specification for unambiguously describing the structure of chemical molecules using short ASCII strings. Canonical SMILES specify a unique representation of the 2D structure without chiral or isotopic specifications. Isomeric SMILES include chiral specification and isotopes.

Standard InChI (IUPAC International Chemical Identifier) and InChIKey InChI is a non-proprietary, standard, textual identifier for chemical substances designed to facilitate linking of information and database searching. An InChIKey is a simplified version of a full InChI, designed for easier web searching.

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

✖
Canonical SMILES CC(C)C[C@@H](C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@H](C)C(=O)O)NC(=O)[C@H](CCSC)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CO)NC(=O)[C@@H](C)N
Isomeric SMILES C[C@H](C(=O)N[C@@H](CO)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@H](C)C(=O)O)N
InChI InChI=1S/C46H72N10O15S/c1-22(2)18-30(52-39(63)29(15-17-72-8)50-43(67)34-10-9-16-56(34)45(69)33(21-57)54-37(61)24(5)47)42(66)55-36(23(3)4)44(68)48-25(6)38(62)51-31(19-27-11-13-28(58)14-12-27)41(65)53-32(20-35(59)60)40(64)49-26(7)46(70)71/h11-14,22-26,29-34,36,57-58H,9-10,15-21,47H2,1-8H3,(H,48,68)(H,49,64)(H,50,67)(H,51,62)(H,52,63)(H,53,65)(H,54,61)(H,55,66)(H,59,60)(H,70,71)/t24-,25+,26-,29+,30+,31+,32+,33+,34+,36+/m1/s1
InChI Key VRNHFZYMPDKTBS-WYUJEMNCSA-N

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)
No information available.
Summary of Clinical Use Click here for help
Reltecimod has completed a Phase 3 clinical trial (NCT02469857) to evaluate safety and efficacy in patients with NSTIs. Although reltecimod did not lower mortality, reduce the need for amputation or reduce the length of hospital admission, early administration of the agent was associated with improved resolution of organ dysfunction [3]. A Phase 3 study (NCT03403751) to assess the safety and efficacy of reltecimod in patients with sepsis-associated acute kidney injury (AKI) was terminated due to slow enrollment.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT02469857 Phase III Efficacy and Safety Study of AB103 in the Treatment of Patients With Necrotizing Soft Tissue Infections Phase 3 Interventional Atox Bio Ltd 3
NCT03403751 Phase 3 Study of Reltecimod vs Placebo in Patients With Sepsis-associated Acute Kidney Injury Phase 3 Interventional Atox Bio Ltd Terminated due to slow enrollment.